ENAapplication/xmlftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/058/SRR13833758/SRR13833758.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/064/SRR13833764/SRR13833764.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/065/SRR13833765/SRR13833765.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/063/SRR13833763/SRR13833763.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/059/SRR13833759/SRR13833759.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/062/SRR13833762/SRR13833762.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/060/SRR13833760/SRR13833760.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/057/SRR13833757/SRR13833757.fastq.gzftp://ftp.sra.ebi.ac.uk/vol1/fastq/SRR138/061/SRR13833761/SRR13833761.fastq.gzprimaryOK200GenomicsSandberg Laboratory, Cell and Molecular Biology, Karolinska Institutethttps://www.ebi.ac.uk/ena/browser/view/PRJNA706026Homo sapiensxref:PubMed:33734579The goal of the study was to identify downstream genes affected by overexpresion on MX2 gene in a huma melanoma cell line WM983 Overall design: 3 groups containing 3 independent replicates: Untreated control cells GFP overexpressing cells MX2 overexpressing cellsENAtreatment, Therapy, melanoma (disease), Melanomas, disease management., Melanoma, melanoma, Therapeutic, malignant, Malignant Melanoma, Naevocarcinoma, Therapies, malignant melanoma, Treatment, Mx-2, MXB, Malignant Melanomas, Interferon, Malignant, AI528743, Treatments, Celltreatment, Therapy, melanoma (disease), Melanomas, disease management., Melanoma, melanoma, Therapeutic, malignant, Malignant Melanoma, Naevocarcinoma, Therapies, malignant melanoma, Treatment, Mx-2, MXB, Malignant Melanomas, Interferon, Malignant, AI528743, Treatments, CellfalseMX2 mediates establishment of interferon response profile, regulates XAF1 and can sensitize melanoma cells to targeted therapyMX2 mediates establishment of interferon response profile, regulates XAF1 and can sensitize melanoma cells to targeted therapy2025-09-242021-03-04PRJNA706026GSE168102960633734579